Mode
Text Size
Log in / Sign up

Impact of Standardized Core Lab Assessment on Outcomes in Three-Vessel DiseaseStandardized testing reveals hidden risks in heart artery procedures

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Standardized QCA and angio-FFR assessments identify more high-risk lesions than site-reported visual assessments.

This randomized controlled trial analysis evaluates the clinical implications of utilizing a standardized assessment protocol for percutaneous coronary intervention (PCI) in patients with three-vessel disease. By comparing site-reported visual assessments against a core lab algorithm incorporating quantitative coronary angiography (QCA) and angiography-based fractional flow reserve (angio-FFR), the study aims to refine the definition of procedural success and its correlation with long-term clinical outcomes.

The study enrolled 1,548 patients with 4,052 lesions. The primary endpoint was a lesion-oriented composite endpoint (LOCE), which included cardiovascular death, target vessel myocardial infarction, or target lesion revascularization over a 12-month follow-up period. This rigorous framework allows for a more nuanced understanding of how technical success, as defined by objective metrics, translates into clinical stability.

Results indicate a significant discrepancy between site-reported success and core lab assessments. While site-reported success was recorded at 97.4%, the success rate using the QCA-based metric was significantly lower at 88.0% (p<0.001). Furthermore, the angio-FFR-based success rate was 93.8% (p<0.001), and the combined QCA and angio-FFR assessment yielded a success rate of 83.2% (p<0.001). These figures suggest that visual assessment may overestimate the technical success of complex lesions.

Clinical correlation was observed between these assessment methods and the LOCE. Lesions that failed to meet the QCA-based success criteria demonstrated a significantly higher 1-year LOCE rate of 12.0% compared to 9.1% for those that met the criteria (log-rank p=0.041). This suggests that objective metrics may better identify high-risk lesions requiring more intensive management or different intervention strategies.

From a clinical perspective, the adoption of the EAPCI-endorsed algorithm provides a more robust framework for evaluating procedural outcomes. By moving away from subjective visual assessments, clinicians can more accurately identify lesions that are technically suboptimal. This distinction is critical in the management of multi-vessel disease, where precise intervention is necessary to mitigate risks of myocardial infarction and revascularization. While this analysis is based on a pre-specified evaluation of the TALENT trial, the findings underscore the value of standardized metrics. The integration of QCA and angio-FFR provides a reproducible method for determining success. These findings suggest that standardized core lab assessments can refine the identification of lesions at higher risk for adverse events, potentially guiding more informed clinical decision-making in complex coronary cases.

When a person has three-vessel disease, it means that three of the main arteries supplying blood to the heart are narrowed or blocked. Treating these blockages is a major step in managing heart health. Doctors often use a procedure called percutaneous coronary intervention, or PCI, to open these vessels. Because these procedures are so important, it is vital that doctors know exactly when a procedure has been successful and when a patient might still be at risk for future complications.

To get a clearer picture, researchers looked at data from a large trial involving 1,548 patients with three-vessel disease. They compared two different ways of measuring success. The first way was the site-reported success, which is how the doctors at the hospital judged the procedure based on what they saw during the operation. The second way was a standardized assessment using a specific set of rules and tools, including a method called QCA (quantitative coronary angiography) and a tool called angio-FFR to measure blood flow.

The results showed a significant gap between the two methods. While the site-reported success rate was 97.4%, the standardized assessment showed much lower success rates. For example, when using only the QCA tool, the success rate was 88.0%. When using the angio-FFR tool, it was 93.8%. When combining both tools for a strict standard, the success rate dropped to 83.2%. Most importantly, the study found that lesions that did not meet the strict standardized criteria had a higher rate of serious problems, such as heart attacks or the need for more procedures, within one year.

It is important to remember that this study is a pre-specified analysis of a larger trial. This means the researchers were looking at specific data points within a bigger study rather than testing a brand-new treatment. Also, the study is comparing two different ways of measuring success, not two different types of surgery or medicine.

For patients right now, this research does not mean that your doctor's current methods are wrong. Instead, it highlights the importance of using precise, standardized tools to ensure every patient gets the best possible care. It suggests that using a more rigorous checklist can help doctors identify which patients might need extra attention after their procedure to prevent future heart issues.

What this means for you:
Standardized tools can help doctors more accurately identify which heart procedures were successful and which carry higher risks.

Study Details

Study typeRct
Sample sizen = 1,548
EvidenceLevel 2
Follow-up12.0 mo
PublishedOct 2026
View Original Abstract ↓
BACKGROUND: The European Association of Percutaneous Cardiovascular Interventions (EAPCI)-endorsed algorithm for defining device success has not yet been prospectively tested against standardised quantitative coronary angiography (QCA) by a core lab. AIMS: We sought to assess whether visually evaluated device success by the operator at the end of percutaneous coronary intervention (PCI) aligns with the EAPCI-endorsed standardised definition adjudicated by the core lab and to evaluate its association with clinical outcomes. METHODS: This prespecified analysis of the Multivessel TALENT trial included 1,548 patients with three-vessel disease randomised to treatment with either Supraflex Cruz or SYNERGY stents. PCI was attempted in 4,052 lesions. The core lab assessed post-PCI residual in-stent percentage diameter stenosis (%DS) by QCA (target <20%) and exploratory delta (Δ) angiography-derived fractional flow reserve (angio-FFR) across the stent(s) (target <0.05). Device success was evaluated using the site-reported data (visual evaluation of in-stent %DS), core lab QCA, core lab angio-FFR, and combined core lab QCA+angio-FFR. The lesion-oriented composite endpoint (LOCE; comprising cardiovascular death, target vessel myocardial infarction, or target lesion revascularisation) was assessed at 1 year. RESULTS: Site-reported device success was 97.4%. Core lab definitions yielded lower rates: 93.8% for Δangio-FFR <0.05, 88.0% for residual %DS <20%, and 83.2% for QCA+angio-FFR (all p<0.001 vs site report after Bonferroni correction). Lesions not meeting QCA-based device success had a higher incidence of LOCE than those meeting the definition (12.0% vs 9.1%; log-rank p=0.041). Device success and LOCE rates did not differ between the two stents for any definition. CONCLUSIONS: In this prespecified lesion-level substudy, standardised assessment using the EAPCI device success algorithm with core lab QCA reclassified a substantial proportion of operator-adjudicated successes and identified lesions at higher 1-year LOCE risk. (ClinicalTrials.gov: NCT04390672).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.